Denna sida på svenska

Hanna Gyllensten

Postdoc

Postal address : Department of Clinical Neuroscience (CNS), K8, Insurance medicine Alexanderson, Berzelius Väg 3, Plan 6 171 77 Stockholm, Sweden
Delivery address : Berzelius Väg 3, Plan 6 171 77 Stockholm, Sweden

Education

2014, PhD (Medicine), University of Gothenburg

Thesis title: Economic impact of drug-related morbidity in Sweden – Estimated using experts’ opinion, medical records and self-reports

Supervisors: Ass Prof Anders Carlsten (main), Prof Clas Rehnberg, PhD Anna Jönsson

 

2004, Master of Science in Pharmacy, Registered pharmacist

Academic honors, awards and prizes

14th European congress för International Society for Pharmacoeconomic and Outcomes Research (ISPOR) in Madrid, Spanien, 5-8 November 2011: Best Student Poster Research Presentations Award.

Documents

Links

Publications

Comparing costs of illness of multiple sclerosis in three different years: A population-based study
Gyllensten H, Wiberg M, Alexanderson K, Friberg E, Hillert J, Tinghög P
Multiple sclerosis (Houndmills, Basingstoke, England) 2017;():1352458517702549-

Income in Multiple Sclerosis Patients with Different Disease Phenotypes
Kavaliunas A, Manouchehrinia A, Danylaite Karrenbauer V, Gyllensten H, Glaser A, Alexanderson K, et al
PloS one 2017;12(1):e0169460-

Cost of Illness of Multiple Sclerosis - A Systematic Review
Ernstsson O, Gyllensten H, Alexanderson K, Tinghög P, Friberg E, Norlund A
PloS one 2016;11(7):e0159129-

Direct and indirect costs for adverse drug events identified in medical records across care levels, and their distribution among payers
Natanaelsson J, Hakkarainen Km, Hägg S, Andersson Sundell K, Petzold M, Rehnberg C, et al
Research in social & administrative pharmacy : RSAP 2016;():-

Effectiveness of person-centred care after acute coronary syndrome in relation to educational level: Subgroup analysis of a two-armed randomised controlled trial
Fors A, Gyllensten H, Swedberg K, Ekman I
International journal of cardiology 2016;221():957-62

How does work disability of patients with MS develop before and after diagnosis? A nationwide cohort study with a reference group
Gyllensten H, Wiberg M, Alexanderson K, Hillert J, Tinghög P
BMJ open 2016;6(11):e012731-

Adherence to Antihypertensive Therapy and Elevated Blood Pressure: Should We Consider the Use of Multiple Medications?
Hedna K, Hakkarainen Km, Gyllensten H, Jönsson Ak, Andersson Sundell K, Petzold M, et al
PloS one 2015;10(9):e0137451-

Costs of Illness of Multiple Sclerosis In Sweden - A Population-Based Register Study
Gyllensten H, Wiberg M, Tinghög P, Norlund A, Friberg E, Ernstsson O, et al
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2015;18(7):A753-4

Earnings and Financial Compensation from Social Security Systems Correlate Strongly with Disability for Multiple Sclerosis Patients
Kavaliunas A, Wiberg M, Tinghög P, Glaser A, Gyllensten H, Alexanderson K, et al
PloS one 2015;10(12):e0145435-

Economic Impact Of Drug-Related Morbidity In Sweden
Gyllensten H
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2015;18(7):A532-

Pharmacoepidemiology at Nordic School of Public Health NHV: Examples from 1999 to 2014
Stålsby Lundborg C, Gyllensten H, Hedna K, Hakkarainen Km, Lesén E, Andersson Sundell K, et al
Scandinavian journal of public health 2015;43(16 Suppl):73-80

Potentially inappropriate prescribing and adverse drug reactions in the elderly: a population-based study
Hedna K, Hakkarainen Km, Gyllensten H, Jönsson Ak, Petzold M, Hägg S
European journal of clinical pharmacology 2015;71(12):1525-33

Economic impact of adverse drug events--a retrospective population-based cohort study of 4970 adults
Gyllensten H, Hakkarainen Km, Hägg S, Carlsten A, Petzold M, Rehnberg C, et al
PloS one 2014;9(3):e92061-

Prevalence, nature and potential preventability of adverse drug events - a population-based medical record study of 4970 adults
Hakkarainen Km, Gyllensten H, Jonsson Ak, Sundell Ka, Petzold M, Hagg S
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 2014;78(1):170-83

Cost of illness of patient-reported adverse drug events: a population-based cross-sectional survey
Gyllensten H, Rehnberg C, Jönsson Ak, Petzold M, Carlsten A, Andersson Sundell K
BMJ open 2013;3(6):-

How are the costs of drug-related morbidity measured?: a systematic literature review
Gyllensten H, Jönsson Ak, Rehnberg C, Carlsten A
Drug safety 2012;35(3):207-19

Modelling drug-related morbidity in Sweden using an expert panel of pharmacists'
Gyllensten H, Hakkarainen Km, Jönsson Ak, Andersson Sundell K, Hägg S, Rehnberg C, et al
International journal of clinical pharmacy 2012;34(4):538-46

Modelling drug-related morbidity in Sweden using an expert panel of physicians
Hakkarainen Km, Alstrom D, Hagg S, Carlsten A, Gyllensten H
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2012;68(9):1309-19

Sweden Pharmacy privatisation rings alarm bell
Gyllensten H
EJHP PRACTICE 2009;15(3):15-15

Show all publications